Nature Communications Publication of the 5hmC Profiles Across Multiple Human Tissue Types
Lays Foundation for Future Diagnostics
December 2, 2020. SAN DIEGO – Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to cancer detection, and University of Chicago today announce the publication of a genome-wide 5-hydroxymethylcytosine (5hmC) map across multiple human tissue types. The study, published in the peer-reviewed journal Nature Communications, demonstrated the robust performance of 5hmC as a global biomarker for the detection of multiple serious illnesses, such as cancer and various chronic diseases. Unlike 5mC which is a gene repression mark, 5hmC is a gene activation mark representing one of the most prevalent pathways involved in the regulation of embryogenesis, neurological processes, and carcinogenesis. The new map advances the understanding of diverse biological drivers in various diseases, which is necessary for the development of next-generation diagnostic tests.
“While previous studies have shown that 5hmC can serve as an excellent biomarker for the diagnosis and prognosis of human diseases including cancer, the lack of a whole-body tissue map limits our global understanding of this mark and its potential tissue specificity,” says Dr. Chuan He, Professor of Chemistry at the University of Chicago and the senior author of the study. “Through this collaboration with Bluestar Genomics, the new publication significantly expands our understanding of this global biomarker, delivering what we believe is the broadest reported human tissue map that catalogs 5hmC modifications. The new map confirms 5hmC as a prevalent gene activation mark for both gene bodies and enhancers with superb tissue and cell type specificity, which is key to future early diagnosis of human cancer and monitoring of human chronic diseases.”
In this study, the University of Chicago scientists collaborated with Bluestar Genomics to evaluate the performance and reproducibility of 5hmC as a biomarker across 19 tissue types from multiple male and female organs. The published results demonstrate that the 5hmC profiles identified in the new map provide an unprecedented database of potential diagnostic development, specifically in cancer.
Based on a study of 96 samples representing ten major organ systems: nervous, cardiovascular, digestive, reproductive, endocrine, respiratory, urinary, integumentary, skeletal, and lymphatic, the map represents the most comprehensive examination of 5hmC as a biomarker for cancer detection. The data confirms the profiling accuracy (Spearman r = 0.82 compared with gold standard TAB-seq profiles) and reproducibility (Spearman r = 0.974) of the genome-wide 5hmC profiles obtained in various tissues, which underscores its clinical relevance and provides a unique resource to study distributions of 5hmC in the human genome.
Building on Bluestar Genomics’ previously published work, the new publication highlights that 5hmC reveals known biology in human tissues by enabling the measurement of gene transcriptional and gene regulation activity with the same assay. The published map, which characterizes the genomic distributions of 5hmC in 19 human tissues derived from ten organ systems lays the foundation for the future development of diagnostic tests.
“With the ultimate goal of developing a robust cancer screening test, this map brings us a step closer to enhancing our ability to accurately read and interpret cancer signals coming from tumor tissues in cell-free DNA,” says Samuel Levy, Ph.D., Chief Executive and Chief Scientific Officer at Bluestar Genomics, co-senior author of the study. “I’m proud that our work will also contribute to the broader scientific community by deepening scientists’ precise understanding of the breadth of biology through the utilization of 5hmC.”
About Bluestar Genomics
Bluestar Genomics develops next-generation epigenomic approaches to detect deadly cancers, like pancreatic, early when curative therapies are possible. Founded out of Dr. Stephen Quake’s Stanford laboratory, Bluestar Genomics combines novel epigenomic technologies with its innovative machine learning architecture to tackle the most urgent challenges such as cancer detection. Leveraging the ease of liquid biopsy technologies, the company’s cell-free DNA-based assays are targeting early cancer detection using simple and noninvasive blood draws to improve outcomes and save lives. Led by a team with decades of experience bringing products from concept to market, Bluestar Genomics is continuously seeking better ways to measure disease pathology and bring its technologies to the patients, clinicians, scientists, and investors searching for tomorrow’s cures. www.bluestargenomics.com
Defining Epigenomics
The epigenome is a multitude of chemical compounds that can tell the genome what to do. The human genome is the complete assembly of DNA (deoxyribonucleic acid) that holds the instructions for building the proteins that carry out a variety of functions in a cell. The epigenome is made up of chemical compounds and proteins that can attach to DNA and direct such actions as turning genes on or off, controlling the production of proteins in particular cells. Although all cells in the body contain essentially the same genome, the DNA marked by chemical tags on the DNA and histones gets rearranged when cells become specialized. The epigenome can also change throughout a person’s lifetime. Cancers are caused by changes in the genome, the epigenome, or both. Changes in the epigenome can switch on or off genes involved in cell growth or the immune response. These changes can lead to uncontrolled growth, a hallmark of cancer, or to a failure of the immune system to destroy tumors.